Merck & Co., Inc. (MRK) stock
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/30106% above fair value
$146.95−0.23 (-0.16%)
Close on Nov 12, 2026Market cap $362.55BP/E 151.5Yield 2.23%
Merck EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Merck's EPS for the twelve months ending Sep 30, 2026 was $0.97, down 87.2% year over year. For fiscal 2025 it was $7.28, up 8.0% from the year before. Over ten years it grew 16.7% a year on average. The highest annual figure on record is $7.28 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.28 | +8.0% |
| FY2024 | Dec 31, 2024 | $6.74 | +4714.3% |
| FY2023 | Dec 31, 2023 | $0.14 | -97.5% |
| FY2022 | Dec 31, 2022 | $5.71 | +11.1% |
| FY2021 | Dec 31, 2021 | $5.14 | +84.9% |
| FY2020 | Dec 31, 2020 | $2.78 | -27.0% |
| FY2019 | Dec 31, 2019 | $3.81 | +64.2% |
| FY2018 | Dec 31, 2018 | $2.32 | +166.7% |
| FY2017 | Dec 31, 2017 | $0.87 | -38.3% |
| FY2016 | Dec 31, 2016 | $1.41 | -9.6% |
| FY2015 | Dec 31, 2015 | $1.56 | -61.7% |
| FY2014 | Dec 31, 2014 | $4.07 | +176.9% |
| FY2013 | Dec 31, 2013 | $1.47 | -26.5% |
| FY2012 | Dec 31, 2012 | $2.00 | -1.0% |
| FY2011 | Dec 31, 2011 | $2.02 | +621.4% |
| FY2010 | Dec 31, 2010 | $0.28 | -95.0% |
| FY2009 | Dec 31, 2009 | $5.65 | +55.6% |
| FY2008 | Dec 31, 2008 | $3.63 | +143.6% |
| FY2007 | Dec 31, 2007 | $1.49 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.04 | -12.1% |
| Q2 FY2026 | Jun 30, 2026 | -$0.54 | -130.7% |
| Q1 FY2026 | Mar 31, 2026 | -$1.72 | -185.6% |
| Q4 FY2025 | Dec 31, 2025 | $1.19 | -19.6% |
| Q3 FY2025 | Sep 30, 2025 | $2.32 | +87.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.76 | -17.8% |
| Q1 FY2025 | Mar 31, 2025 | $2.01 | +7.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.48 | – |
| Q3 FY2024 | Sep 30, 2024 | $1.24 | -33.3% |
| Q2 FY2024 | Jun 30, 2024 | $2.14 | – |
| Q1 FY2024 | Mar 31, 2024 | $1.87 | +68.5% |
| Q4 FY2023 | Dec 31, 2023 | -$0.48 | -140.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.86 | +45.3% |
| Q2 FY2023 | Jun 30, 2023 | -$2.35 | -251.6% |
| Q1 FY2023 | Mar 31, 2023 | $1.11 | -34.7% |
| Q4 FY2022 | Dec 31, 2022 | $1.18 | -20.3% |
| Q3 FY2022 | Sep 30, 2022 | $1.28 | -28.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.55 | +154.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.70 | +36.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.48 | – |
| Q3 FY2021 | Sep 30, 2021 | $1.80 | +55.2% |
| Q2 FY2021 | Jun 30, 2021 | $0.61 | -48.3% |
| Q1 FY2021 | Mar 31, 2021 | $1.25 | -0.8% |
| Q4 FY2020 | Dec 31, 2020 | -$0.82 | -189.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.16 | +56.8% |
| Q2 FY2020 | Jun 30, 2020 | $1.18 | +14.6% |
| Q1 FY2020 | Mar 31, 2020 | $1.26 | +12.5% |
| Q4 FY2019 | Dec 31, 2019 | $0.92 | +33.3% |
| Q3 FY2019 | Sep 30, 2019 | $0.74 | +1.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.03 | +63.5% |
| Q1 FY2019 | Mar 31, 2019 | $1.12 | +314.8% |
| Q4 FY2018 | Dec 31, 2018 | $0.69 | – |
| Q3 FY2018 | Sep 30, 2018 | $0.73 | – |
| Q2 FY2018 | Jun 30, 2018 | $0.63 | -11.3% |
| Q1 FY2018 | Mar 31, 2018 | $0.27 | -51.8% |
| Q4 FY2017 | Dec 31, 2017 | -$0.38 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.02 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.71 | – |
| Q1 FY2017 | Mar 31, 2017 | $0.56 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.21 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?